Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2002-04

AUTHORS

F Maloisel, A Guerci, D Guyotat, N Ifrah, M Michallet, J Reiffers, G Tertain, M Blanc, F Bauduer, J Brière, JF Abgrall, B Pegourie-Bandelier, E Solary, N Cambier, D Coso, JP Vilque, M Delain, JL Harousseau, P Rousselot, K Belhadj, P Morice, J Attal, M Chabin, C Chastang, J Guilhot, F Guilhot

ABSTRACT

Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral administration. Following initial studies indicating significant anti-tumour activity of YNK01 a phase II trial was initiated in order to assess the tolerability and efficacy of a combination of this agent with interferon alpha-2b (IFN-alpha2b) in recently diagnosed chronic phase CML patients (n = 98). The treatment was subdivided into cycles consisting of 4 weeks of continuous administration of IFN-alpha-2b (3 MU/m(2)/day 1st week and then 5 MU/m(2)/day) and 14 days of oral YNK01 (600 mg/day 1st cycle). At the end of each cycle the dose of YNK01 was adjusted according to the blood count observed during the previous 4 weeks. The median time from diagnosis to inclusion in the trial was 2 months (range 6 days to 7.5 months). At 12 weeks, 62 patients (63%; 95% CI, 54-73) achieved a complete hematological response. At 24 weeks, of 98 patients, two achieved a complete cytogenetic response, 14 a partial response (16% major cytogenetic response rate; 95% CI, 9-24) and 34 a minor response; 19 patients were not evaluable for cytogenetic response. During the trial, 20 patients progressed to accelerated (6) or blastic phases (14). The median time to progression was 15 months (range 2-38 months). At 3 years the overall survival was 79% (95% CI, 70-88). Although the complete hematological response rate compared favorably with the 40% response rate previously obtained with the subcutaneous formulation of Ara-c, the cytogenetic response rate was less than expected. Most of the patients experienced side-effects and all permanently stopped YNK01. Although the combination seems attractive the initial dose of 600 mg per day is probably too high and should be reconsidered in further trials. More... »

PAGES

2402433

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.leu.2402433

DOI

http://dx.doi.org/10.1038/sj.leu.2402433

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000443764

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11960335


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arabinonucleotides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytidine Monophosphate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon alpha-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Chronic-Phase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "H\u00f4pitaux Universitaires de Strasbourg", 
          "id": "https://www.grid.ac/institutes/grid.412220.7", 
          "name": [
            "Division of Hematology, University Hospital of Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maloisel", 
        "givenName": "F", 
        "id": "sg:person.0576230340.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576230340.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Nancy", 
          "id": "https://www.grid.ac/institutes/grid.410527.5", 
          "name": [
            "Division of Hematology, University Hospital of Nancy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guerci", 
        "givenName": "A", 
        "id": "sg:person.013453755754.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013453755754.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Saint Etienne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guyotat", 
        "givenName": "D", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Angers", 
          "id": "https://www.grid.ac/institutes/grid.411147.6", 
          "name": [
            "Division of Hematology, University Hospital of Angers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ifrah", 
        "givenName": "N", 
        "id": "sg:person.0772462561.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772462561.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospices Civils de Lyon", 
          "id": "https://www.grid.ac/institutes/grid.413852.9", 
          "name": [
            "Division of Hematology, University Hospital of Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michallet", 
        "givenName": "M", 
        "id": "sg:person.01264301106.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264301106.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Bordeaux", 
          "id": "https://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "Division of Hematology, University Hospital of Bordeaux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reiffers", 
        "givenName": "J", 
        "id": "sg:person.01230203137.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230203137.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Le Kremlin Bic\u00eatre, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tertain", 
        "givenName": "G", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Annecy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanc", 
        "givenName": "M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Bayonne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauduer", 
        "givenName": "F", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bri\u00e8re", 
        "givenName": "J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier R\u00e9gional Universitaire de Brest", 
          "id": "https://www.grid.ac/institutes/grid.411766.3", 
          "name": [
            "Division of Hematology, University Hospital of Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abgrall", 
        "givenName": "JF", 
        "id": "sg:person.015301123334.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301123334.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, Grenoble, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pegourie-Bandelier", 
        "givenName": "B", 
        "id": "sg:person.01046515366.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046515366.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Regional Universitaire De Dijon", 
          "id": "https://www.grid.ac/institutes/grid.31151.37", 
          "name": [
            "Division of Hematology, University Hospital of Dijon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Solary", 
        "givenName": "E", 
        "id": "sg:person.0636060620.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636060620.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cambier", 
        "givenName": "N", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coso", 
        "givenName": "D", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Quimper, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vilque", 
        "givenName": "JP", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Tours", 
          "id": "https://www.grid.ac/institutes/grid.411167.4", 
          "name": [
            "Division of Hematology, University Hospital of Tours, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Delain", 
        "givenName": "M", 
        "id": "sg:person.0774655407.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774655407.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Nantes", 
          "id": "https://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Division of Hematology, University of Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harousseau", 
        "givenName": "JL", 
        "id": "sg:person.0774254522.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774254522.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, Saint Louis, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousselot", 
        "givenName": "P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University of Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Belhadj", 
        "givenName": "K", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, University Hospital of Saint Brieuc, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morice", 
        "givenName": "P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Toulouse", 
          "id": "https://www.grid.ac/institutes/grid.11417.32", 
          "name": [
            "Division of Hematology, University of Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Attal", 
        "givenName": "J", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers", 
          "id": "https://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Oncology-Hematology and Cell Therapy, CHU la Mil\u00e9trie, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chabin", 
        "givenName": "M", 
        "id": "sg:person.0662266747.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662266747.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Division of Hematology, Saint Louis, Department of Statistiques, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chastang", 
        "givenName": "C", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers", 
          "id": "https://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Oncology-Hematology and Cell Therapy, CHU la Mil\u00e9trie, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guilhot", 
        "givenName": "J", 
        "id": "sg:person.01175423771.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175423771.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers", 
          "id": "https://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Oncology-Hematology and Cell Therapy, CHU la Mil\u00e9trie, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guilhot", 
        "givenName": "F", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2401152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000906370", 
          "https://doi.org/10.1038/sj.leu.2401152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000906370", 
          "https://doi.org/10.1038/sj.leu.2401152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.7.1999", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016542408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19870101)59:1<197::aid-cncr2820590137>3.0.co;2-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025559740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200104053441401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026812584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/89.21.1616", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030905401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428199109107057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032104462"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199707243370402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034926285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0145-2126(88)90110-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046567189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.2830430205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046609338"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)92596-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046662985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(95)92596-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046662985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0145-2126(00)00036-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049709484"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.2.3.463", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071511949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-114-7-532", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073695388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.1.284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074511238"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.20.3513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074712505"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.5.772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077003816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082438032", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082599630", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082707177", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083309626", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2002-04", 
    "datePublishedReg": "2002-04-01", 
    "description": "Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral administration. Following initial studies indicating significant anti-tumour activity of YNK01 a phase II trial was initiated in order to assess the tolerability and efficacy of a combination of this agent with interferon alpha-2b (IFN-alpha2b) in recently diagnosed chronic phase CML patients (n = 98). The treatment was subdivided into cycles consisting of 4 weeks of continuous administration of IFN-alpha-2b (3 MU/m(2)/day 1st week and then 5 MU/m(2)/day) and 14 days of oral YNK01 (600 mg/day 1st cycle). At the end of each cycle the dose of YNK01 was adjusted according to the blood count observed during the previous 4 weeks. The median time from diagnosis to inclusion in the trial was 2 months (range 6 days to 7.5 months). At 12 weeks, 62 patients (63%; 95% CI, 54-73) achieved a complete hematological response. At 24 weeks, of 98 patients, two achieved a complete cytogenetic response, 14 a partial response (16% major cytogenetic response rate; 95% CI, 9-24) and 34 a minor response; 19 patients were not evaluable for cytogenetic response. During the trial, 20 patients progressed to accelerated (6) or blastic phases (14). The median time to progression was 15 months (range 2-38 months). At 3 years the overall survival was 79% (95% CI, 70-88). Although the complete hematological response rate compared favorably with the 40% response rate previously obtained with the subcutaneous formulation of Ara-c, the cytogenetic response rate was less than expected. Most of the patients experienced side-effects and all permanently stopped YNK01. Although the combination seems attractive the initial dose of 600 mg per day is probably too high and should be reconsidered in further trials.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.leu.2402433", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon \u03b1-2b for the treatment of chronic myelogenous leukemia patients in chronic phase", 
    "pagination": "2402433", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "021cea48eacab5719ba8517be8a4473ff11ec58d826269b518dd8ba293b0d00e"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11960335"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.leu.2402433"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000443764"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.leu.2402433", 
      "https://app.dimensions.ai/details/publication/pub.1000443764"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29181_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/articles/2402433"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402433'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402433'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402433'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2402433'


 

This table displays all metadata directly associated to this object as RDF triples.

427 TRIPLES      21 PREDICATES      70 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.leu.2402433 schema:about N01a4a6146ce6434d88547115cf0ce1aa
2 N024ab374573d489dbe50090a27da3cfa
3 N19489197d29f4bbcb868a172e4a3ea08
4 N1e28fa16a90542b8b7beed7d031123d3
5 N25ac7377361d468b81530296e5d7ef46
6 N3164ea19e85e46c8ba0d117cad193fe6
7 N3723f85440674f02a4db9f4e16454479
8 N678b522602684deaacf0c69b701a78d3
9 N7cf56011277e4efa87d1398169c19118
10 N8904f01560bf48e68d330cd2fa207922
11 N9bf6a97c99d74604b4ea45e16147d008
12 Nb017b3f393114c8f934886f14819834d
13 Nb4267ea339684f8a808f703f7c600e02
14 Nb5f8890f5dfe4f1283e6e4aec2946a19
15 Ncb9598fcc4364db29b780e52ac588ee1
16 Nce35ec248f8842cb8d2116e3f87e8898
17 Ndc5bfb7b1d3a4e368590d58202fd7729
18 Ndf8c7c00d31e42ec9c3d6c97f9b4c4f7
19 Ne7ed3bfb25794b8dbbb34f696157c8cc
20 Nee60bdeb09ea4fccbf711badb976f7df
21 Nf590b0918e9d452cb48997a6731a4b21
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N018e5c1bf69f4193a1505216bfa6e17f
25 schema:citation sg:pub.10.1038/sj.leu.2401152
26 https://app.dimensions.ai/details/publication/pub.1082438032
27 https://app.dimensions.ai/details/publication/pub.1082599630
28 https://app.dimensions.ai/details/publication/pub.1082707177
29 https://app.dimensions.ai/details/publication/pub.1083309626
30 https://doi.org/10.1002/1097-0142(19870101)59:1<197::aid-cncr2820590137>3.0.co;2-8
31 https://doi.org/10.1002/ajh.2830430205
32 https://doi.org/10.1016/0145-2126(88)90110-5
33 https://doi.org/10.1016/s0140-6736(95)92596-1
34 https://doi.org/10.1016/s0145-2126(00)00036-9
35 https://doi.org/10.1056/nejm199707243370402
36 https://doi.org/10.1056/nejm200104053441401
37 https://doi.org/10.1093/jnci/89.21.1616
38 https://doi.org/10.1182/blood.v97.7.1999
39 https://doi.org/10.1200/jco.1992.10.5.772
40 https://doi.org/10.1200/jco.1999.17.1.284
41 https://doi.org/10.1200/jco.2000.18.20.3513
42 https://doi.org/10.3109/10428199109107057
43 https://doi.org/10.3892/ijo.2.3.463
44 https://doi.org/10.7326/0003-4819-114-7-532
45 schema:datePublished 2002-04
46 schema:datePublishedReg 2002-04-01
47 schema:description Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral administration. Following initial studies indicating significant anti-tumour activity of YNK01 a phase II trial was initiated in order to assess the tolerability and efficacy of a combination of this agent with interferon alpha-2b (IFN-alpha2b) in recently diagnosed chronic phase CML patients (n = 98). The treatment was subdivided into cycles consisting of 4 weeks of continuous administration of IFN-alpha-2b (3 MU/m(2)/day 1st week and then 5 MU/m(2)/day) and 14 days of oral YNK01 (600 mg/day 1st cycle). At the end of each cycle the dose of YNK01 was adjusted according to the blood count observed during the previous 4 weeks. The median time from diagnosis to inclusion in the trial was 2 months (range 6 days to 7.5 months). At 12 weeks, 62 patients (63%; 95% CI, 54-73) achieved a complete hematological response. At 24 weeks, of 98 patients, two achieved a complete cytogenetic response, 14 a partial response (16% major cytogenetic response rate; 95% CI, 9-24) and 34 a minor response; 19 patients were not evaluable for cytogenetic response. During the trial, 20 patients progressed to accelerated (6) or blastic phases (14). The median time to progression was 15 months (range 2-38 months). At 3 years the overall survival was 79% (95% CI, 70-88). Although the complete hematological response rate compared favorably with the 40% response rate previously obtained with the subcutaneous formulation of Ara-c, the cytogenetic response rate was less than expected. Most of the patients experienced side-effects and all permanently stopped YNK01. Although the combination seems attractive the initial dose of 600 mg per day is probably too high and should be reconsidered in further trials.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree true
51 schema:isPartOf N1d8685448d974acbacb15e084961082e
52 N2f17aa8451f94d03924a3e6fe14f1055
53 sg:journal.1097065
54 schema:name Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
55 schema:pagination 2402433
56 schema:productId N67e4f9f31d4e447589090dd24223b0ff
57 N90563a8e670c4e5aa734e75751a9a8fe
58 Nb6c04c118be44655aa72255cb921b55c
59 Nc6d0d8d5fa8a47d69af41cb4f23c8919
60 Ncd408eed42fd406bb1355f91d2d54af1
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000443764
62 https://doi.org/10.1038/sj.leu.2402433
63 schema:sdDatePublished 2019-04-11T11:50
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher Nb7d8a3ef9b944b349d758f5d91aaa678
66 schema:url http://www.nature.com/articles/2402433
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N0169b165110b465bb5da260814ff8fe1 schema:name Division of Hematology, University Hospital of Saint Etienne, France
71 rdf:type schema:Organization
72 N017471d32fb74339863b236132f9c63f rdf:first sg:person.013453755754.52
73 rdf:rest N8c243a15dc1047cdace9c66158937faf
74 N018e5c1bf69f4193a1505216bfa6e17f rdf:first sg:person.0576230340.76
75 rdf:rest N017471d32fb74339863b236132f9c63f
76 N01a4a6146ce6434d88547115cf0ce1aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Arabinonucleotides
78 rdf:type schema:DefinedTerm
79 N024ab374573d489dbe50090a27da3cfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Administration, Oral
81 rdf:type schema:DefinedTerm
82 N062a8f11972c4253aa781ae042303c96 schema:name Division of Hematology, University of Créteil, France
83 rdf:type schema:Organization
84 N09fb3e697a784b53a79ba23dd9dedf65 rdf:first N71f35a0f426e44e2bf2e9f57bbd4b3fd
85 rdf:rest rdf:nil
86 N0b57bc81140a4d0a9f90af4c3f6615e4 rdf:first N6b797053a6c645d2a4adc60640f5b468
87 rdf:rest Nbd89cf1ab72a4ad981bfcdfdd8929e4a
88 N0e06e0c6e66b42159ab044c43fec9c17 rdf:first Nb6fcb7cd4a9742e18c14385d475e4d94
89 rdf:rest Nc3076e003c0e447286daa890a14f8d82
90 N0f50b43f8f624cada192938956278a18 rdf:first Nef3b72ec4a1d40e49b8e9bbd9692779b
91 rdf:rest N2899a5609e174458a61ec123d41e24da
92 N1144bef374c64cbb98c01e353795ee3e rdf:first sg:person.01230203137.18
93 rdf:rest N216211743b9d441eacc223e1ed9a2821
94 N19489197d29f4bbcb868a172e4a3ea08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Interferon-alpha
96 rdf:type schema:DefinedTerm
97 N1d8685448d974acbacb15e084961082e schema:volumeNumber 16
98 rdf:type schema:PublicationVolume
99 N1e28fa16a90542b8b7beed7d031123d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Female
101 rdf:type schema:DefinedTerm
102 N216211743b9d441eacc223e1ed9a2821 rdf:first N5c7b566fb06f4ab9a2a60930533f0805
103 rdf:rest N0b57bc81140a4d0a9f90af4c3f6615e4
104 N25ac7377361d468b81530296e5d7ef46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Dose-Response Relationship, Drug
106 rdf:type schema:DefinedTerm
107 N2899a5609e174458a61ec123d41e24da rdf:first Ne3f5eab3bc9e4adbb3695787fcda5536
108 rdf:rest N84b8b72cef9b4b7aae7bddcd4c77ce69
109 N2b2b49fc575c4336a6be8229fdc6a6c1 rdf:first sg:person.01264301106.83
110 rdf:rest N1144bef374c64cbb98c01e353795ee3e
111 N2f17aa8451f94d03924a3e6fe14f1055 schema:issueNumber 4
112 rdf:type schema:PublicationIssue
113 N3164ea19e85e46c8ba0d117cad193fe6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Male
115 rdf:type schema:DefinedTerm
116 N31d8709c292d4cb99b401309eb08a3f0 rdf:first sg:person.015301123334.59
117 rdf:rest Nf404ee5705ed4870b58486fdcbfe2336
118 N3723f85440674f02a4db9f4e16454479 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Interferon alpha-2
120 rdf:type schema:DefinedTerm
121 N42bfeeb2b0c94d9594a68baf693198c3 rdf:first sg:person.0662266747.16
122 rdf:rest N9880447ef6cd455fb7e1027e185ad6b9
123 N48e10f95930243869790f6da00fcc437 rdf:first sg:person.0774655407.97
124 rdf:rest Nce672edf32f1430795e327a363d9fac5
125 N4b0a6107128e428da1f0c4d187dc4828 schema:affiliation N7f956cc9caec43139d45d3f3de4d89e3
126 schema:familyName Vilque
127 schema:givenName JP
128 rdf:type schema:Person
129 N4ea4d0fa068e4473b854dfa4037f4721 rdf:first Ndf03047220cc4f1699c703235439e8d8
130 rdf:rest N0e06e0c6e66b42159ab044c43fec9c17
131 N52c30d4073c847f88429d76e04f4dea9 schema:name Division of Hematology, University Hospital of Clichy, France
132 rdf:type schema:Organization
133 N584beb5b6f7c4f4887f10bf0aec1209b schema:name Division of Hematology, Saint Louis, Department of Statistiques, Paris, France
134 rdf:type schema:Organization
135 N5c51142e48b64ddd80f0d8731160b1f4 schema:name Division of Hematology, University Hospital of Le Kremlin Bicêtre, France
136 rdf:type schema:Organization
137 N5c7b566fb06f4ab9a2a60930533f0805 schema:affiliation N5c51142e48b64ddd80f0d8731160b1f4
138 schema:familyName Tertain
139 schema:givenName G
140 rdf:type schema:Person
141 N678b522602684deaacf0c69b701a78d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Survival Rate
143 rdf:type schema:DefinedTerm
144 N67cddf20c0424378a7188949b069b3e3 schema:affiliation https://www.grid.ac/institutes/grid.11417.32
145 schema:familyName Attal
146 schema:givenName J
147 rdf:type schema:Person
148 N67e4f9f31d4e447589090dd24223b0ff schema:name pubmed_id
149 schema:value 11960335
150 rdf:type schema:PropertyValue
151 N6b797053a6c645d2a4adc60640f5b468 schema:affiliation Nc6e1f3e150914a69a3d5ba8bbfda3dba
152 schema:familyName Blanc
153 schema:givenName M
154 rdf:type schema:Person
155 N6cd77f162c214af6bc71b66913f85fe2 schema:affiliation N52c30d4073c847f88429d76e04f4dea9
156 schema:familyName Brière
157 schema:givenName J
158 rdf:type schema:Person
159 N6db5097fe528436e9a3985bb85a6c833 schema:name Division of Hematology, Saint Louis, Paris, France
160 rdf:type schema:Organization
161 N71f35a0f426e44e2bf2e9f57bbd4b3fd schema:affiliation https://www.grid.ac/institutes/grid.411162.1
162 schema:familyName Guilhot
163 schema:givenName F
164 rdf:type schema:Person
165 N736e548d4154464eb3182ef3028d31dd rdf:first sg:person.0772462561.54
166 rdf:rest N2b2b49fc575c4336a6be8229fdc6a6c1
167 N73e5ee8c868f4b888fcb04118f8f8d3e rdf:first sg:person.0636060620.30
168 rdf:rest N0f50b43f8f624cada192938956278a18
169 N7a5c0700a74241c8ae6ba85e21e4f2eb schema:name Division of Hematology, Grenoble, France
170 rdf:type schema:Organization
171 N7cf56011277e4efa87d1398169c19118 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Leukemia, Myeloid, Chronic-Phase
173 rdf:type schema:DefinedTerm
174 N7f956cc9caec43139d45d3f3de4d89e3 schema:name Division of Hematology, University Hospital of Quimper, France
175 rdf:type schema:Organization
176 N809e097f9a794153b515a19bff150c1b schema:name Division of Hematology, University Hospital of Saint Brieuc, France
177 rdf:type schema:Organization
178 N80a9c20dc78647bfb894877cb2bd9f18 rdf:first N6cd77f162c214af6bc71b66913f85fe2
179 rdf:rest N31d8709c292d4cb99b401309eb08a3f0
180 N8387b4b82dd34bdfb7b2b476d0279c75 schema:name Division of Hematology, University Hospital of Bayonne, France
181 rdf:type schema:Organization
182 N84b8b72cef9b4b7aae7bddcd4c77ce69 rdf:first N4b0a6107128e428da1f0c4d187dc4828
183 rdf:rest N48e10f95930243869790f6da00fcc437
184 N877103d9823f486693c15e12c0d0567b schema:affiliation N584beb5b6f7c4f4887f10bf0aec1209b
185 schema:familyName Chastang
186 schema:givenName C
187 rdf:type schema:Person
188 N8904f01560bf48e68d330cd2fa207922 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Humans
190 rdf:type schema:DefinedTerm
191 N8c243a15dc1047cdace9c66158937faf rdf:first Ncd6681a0c592495e9006b181ff41f0fe
192 rdf:rest N736e548d4154464eb3182ef3028d31dd
193 N90563a8e670c4e5aa734e75751a9a8fe schema:name dimensions_id
194 schema:value pub.1000443764
195 rdf:type schema:PropertyValue
196 N9880447ef6cd455fb7e1027e185ad6b9 rdf:first N877103d9823f486693c15e12c0d0567b
197 rdf:rest Nd9c87c62fa51403f9ce831007549099b
198 N9bf6a97c99d74604b4ea45e16147d008 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Aged
200 rdf:type schema:DefinedTerm
201 N9d117c215f9a477a9de6b136f391ee3d schema:name Division of Hematology, Lille, France
202 rdf:type schema:Organization
203 Nb017b3f393114c8f934886f14819834d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Middle Aged
205 rdf:type schema:DefinedTerm
206 Nb4267ea339684f8a808f703f7c600e02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Adolescent
208 rdf:type schema:DefinedTerm
209 Nb5a0949330e94d66a6dac2a485909c28 schema:affiliation N6db5097fe528436e9a3985bb85a6c833
210 schema:familyName Rousselot
211 schema:givenName P
212 rdf:type schema:Person
213 Nb5f8890f5dfe4f1283e6e4aec2946a19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Adult
215 rdf:type schema:DefinedTerm
216 Nb6c04c118be44655aa72255cb921b55c schema:name doi
217 schema:value 10.1038/sj.leu.2402433
218 rdf:type schema:PropertyValue
219 Nb6fcb7cd4a9742e18c14385d475e4d94 schema:affiliation N809e097f9a794153b515a19bff150c1b
220 schema:familyName Morice
221 schema:givenName P
222 rdf:type schema:Person
223 Nb7d8a3ef9b944b349d758f5d91aaa678 schema:name Springer Nature - SN SciGraph project
224 rdf:type schema:Organization
225 Nbd89cf1ab72a4ad981bfcdfdd8929e4a rdf:first Nc837aa6e528345c39ccf5da001d1ea80
226 rdf:rest N80a9c20dc78647bfb894877cb2bd9f18
227 Nc3076e003c0e447286daa890a14f8d82 rdf:first N67cddf20c0424378a7188949b069b3e3
228 rdf:rest N42bfeeb2b0c94d9594a68baf693198c3
229 Nc6d0d8d5fa8a47d69af41cb4f23c8919 schema:name nlm_unique_id
230 schema:value 8704895
231 rdf:type schema:PropertyValue
232 Nc6e1f3e150914a69a3d5ba8bbfda3dba schema:name Division of Hematology, University Hospital of Annecy, France
233 rdf:type schema:Organization
234 Nc837aa6e528345c39ccf5da001d1ea80 schema:affiliation N8387b4b82dd34bdfb7b2b476d0279c75
235 schema:familyName Bauduer
236 schema:givenName F
237 rdf:type schema:Person
238 Ncb9598fcc4364db29b780e52ac588ee1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Recombinant Proteins
240 rdf:type schema:DefinedTerm
241 Ncd408eed42fd406bb1355f91d2d54af1 schema:name readcube_id
242 schema:value 021cea48eacab5719ba8517be8a4473ff11ec58d826269b518dd8ba293b0d00e
243 rdf:type schema:PropertyValue
244 Ncd6681a0c592495e9006b181ff41f0fe schema:affiliation N0169b165110b465bb5da260814ff8fe1
245 schema:familyName Guyotat
246 schema:givenName D
247 rdf:type schema:Person
248 Nce35ec248f8842cb8d2116e3f87e8898 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
249 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
250 rdf:type schema:DefinedTerm
251 Nce672edf32f1430795e327a363d9fac5 rdf:first sg:person.0774254522.22
252 rdf:rest Nef1d6be9e4a042068b2e7c015a32cbb4
253 Nd9c87c62fa51403f9ce831007549099b rdf:first sg:person.01175423771.95
254 rdf:rest N09fb3e697a784b53a79ba23dd9dedf65
255 Ndc5bfb7b1d3a4e368590d58202fd7729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name Cytidine Monophosphate
257 rdf:type schema:DefinedTerm
258 Ndf03047220cc4f1699c703235439e8d8 schema:affiliation N062a8f11972c4253aa781ae042303c96
259 schema:familyName Belhadj
260 schema:givenName K
261 rdf:type schema:Person
262 Ndf8c7c00d31e42ec9c3d6c97f9b4c4f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
263 schema:name Risk Factors
264 rdf:type schema:DefinedTerm
265 Ne3f5eab3bc9e4adbb3695787fcda5536 schema:affiliation Nf05e6d60c2e54e818565c685174a88ac
266 schema:familyName Coso
267 schema:givenName D
268 rdf:type schema:Person
269 Ne7ed3bfb25794b8dbbb34f696157c8cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
270 schema:name Antineoplastic Combined Chemotherapy Protocols
271 rdf:type schema:DefinedTerm
272 Nee60bdeb09ea4fccbf711badb976f7df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
273 schema:name Follow-Up Studies
274 rdf:type schema:DefinedTerm
275 Nef1d6be9e4a042068b2e7c015a32cbb4 rdf:first Nb5a0949330e94d66a6dac2a485909c28
276 rdf:rest N4ea4d0fa068e4473b854dfa4037f4721
277 Nef3b72ec4a1d40e49b8e9bbd9692779b schema:affiliation N9d117c215f9a477a9de6b136f391ee3d
278 schema:familyName Cambier
279 schema:givenName N
280 rdf:type schema:Person
281 Nf05e6d60c2e54e818565c685174a88ac schema:name Division of Hematology, Marseille, France
282 rdf:type schema:Organization
283 Nf404ee5705ed4870b58486fdcbfe2336 rdf:first sg:person.01046515366.81
284 rdf:rest N73e5ee8c868f4b888fcb04118f8f8d3e
285 Nf590b0918e9d452cb48997a6731a4b21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
286 schema:name Prognosis
287 rdf:type schema:DefinedTerm
288 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
289 schema:name Medical and Health Sciences
290 rdf:type schema:DefinedTerm
291 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
292 schema:name Clinical Sciences
293 rdf:type schema:DefinedTerm
294 sg:journal.1097065 schema:issn 0887-6924
295 1476-5551
296 schema:name Leukemia
297 rdf:type schema:Periodical
298 sg:person.01046515366.81 schema:affiliation N7a5c0700a74241c8ae6ba85e21e4f2eb
299 schema:familyName Pegourie-Bandelier
300 schema:givenName B
301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046515366.81
302 rdf:type schema:Person
303 sg:person.01175423771.95 schema:affiliation https://www.grid.ac/institutes/grid.411162.1
304 schema:familyName Guilhot
305 schema:givenName J
306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175423771.95
307 rdf:type schema:Person
308 sg:person.01230203137.18 schema:affiliation https://www.grid.ac/institutes/grid.42399.35
309 schema:familyName Reiffers
310 schema:givenName J
311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230203137.18
312 rdf:type schema:Person
313 sg:person.01264301106.83 schema:affiliation https://www.grid.ac/institutes/grid.413852.9
314 schema:familyName Michallet
315 schema:givenName M
316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264301106.83
317 rdf:type schema:Person
318 sg:person.013453755754.52 schema:affiliation https://www.grid.ac/institutes/grid.410527.5
319 schema:familyName Guerci
320 schema:givenName A
321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013453755754.52
322 rdf:type schema:Person
323 sg:person.015301123334.59 schema:affiliation https://www.grid.ac/institutes/grid.411766.3
324 schema:familyName Abgrall
325 schema:givenName JF
326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301123334.59
327 rdf:type schema:Person
328 sg:person.0576230340.76 schema:affiliation https://www.grid.ac/institutes/grid.412220.7
329 schema:familyName Maloisel
330 schema:givenName F
331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576230340.76
332 rdf:type schema:Person
333 sg:person.0636060620.30 schema:affiliation https://www.grid.ac/institutes/grid.31151.37
334 schema:familyName Solary
335 schema:givenName E
336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636060620.30
337 rdf:type schema:Person
338 sg:person.0662266747.16 schema:affiliation https://www.grid.ac/institutes/grid.411162.1
339 schema:familyName Chabin
340 schema:givenName M
341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662266747.16
342 rdf:type schema:Person
343 sg:person.0772462561.54 schema:affiliation https://www.grid.ac/institutes/grid.411147.6
344 schema:familyName Ifrah
345 schema:givenName N
346 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772462561.54
347 rdf:type schema:Person
348 sg:person.0774254522.22 schema:affiliation https://www.grid.ac/institutes/grid.4817.a
349 schema:familyName Harousseau
350 schema:givenName JL
351 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774254522.22
352 rdf:type schema:Person
353 sg:person.0774655407.97 schema:affiliation https://www.grid.ac/institutes/grid.411167.4
354 schema:familyName Delain
355 schema:givenName M
356 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774655407.97
357 rdf:type schema:Person
358 sg:pub.10.1038/sj.leu.2401152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000906370
359 https://doi.org/10.1038/sj.leu.2401152
360 rdf:type schema:CreativeWork
361 https://app.dimensions.ai/details/publication/pub.1082438032 schema:CreativeWork
362 https://app.dimensions.ai/details/publication/pub.1082599630 schema:CreativeWork
363 https://app.dimensions.ai/details/publication/pub.1082707177 schema:CreativeWork
364 https://app.dimensions.ai/details/publication/pub.1083309626 schema:CreativeWork
365 https://doi.org/10.1002/1097-0142(19870101)59:1<197::aid-cncr2820590137>3.0.co;2-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025559740
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1002/ajh.2830430205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046609338
368 rdf:type schema:CreativeWork
369 https://doi.org/10.1016/0145-2126(88)90110-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046567189
370 rdf:type schema:CreativeWork
371 https://doi.org/10.1016/s0140-6736(95)92596-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046662985
372 rdf:type schema:CreativeWork
373 https://doi.org/10.1016/s0145-2126(00)00036-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049709484
374 rdf:type schema:CreativeWork
375 https://doi.org/10.1056/nejm199707243370402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034926285
376 rdf:type schema:CreativeWork
377 https://doi.org/10.1056/nejm200104053441401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026812584
378 rdf:type schema:CreativeWork
379 https://doi.org/10.1093/jnci/89.21.1616 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030905401
380 rdf:type schema:CreativeWork
381 https://doi.org/10.1182/blood.v97.7.1999 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016542408
382 rdf:type schema:CreativeWork
383 https://doi.org/10.1200/jco.1992.10.5.772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077003816
384 rdf:type schema:CreativeWork
385 https://doi.org/10.1200/jco.1999.17.1.284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074511238
386 rdf:type schema:CreativeWork
387 https://doi.org/10.1200/jco.2000.18.20.3513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074712505
388 rdf:type schema:CreativeWork
389 https://doi.org/10.3109/10428199109107057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032104462
390 rdf:type schema:CreativeWork
391 https://doi.org/10.3892/ijo.2.3.463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071511949
392 rdf:type schema:CreativeWork
393 https://doi.org/10.7326/0003-4819-114-7-532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073695388
394 rdf:type schema:CreativeWork
395 https://www.grid.ac/institutes/grid.11417.32 schema:alternateName University of Toulouse
396 schema:name Division of Hematology, University of Toulouse, France
397 rdf:type schema:Organization
398 https://www.grid.ac/institutes/grid.31151.37 schema:alternateName Centre Hospitalier Regional Universitaire De Dijon
399 schema:name Division of Hematology, University Hospital of Dijon, France
400 rdf:type schema:Organization
401 https://www.grid.ac/institutes/grid.410527.5 schema:alternateName Centre Hospitalier Universitaire de Nancy
402 schema:name Division of Hematology, University Hospital of Nancy, France
403 rdf:type schema:Organization
404 https://www.grid.ac/institutes/grid.411147.6 schema:alternateName Centre Hospitalier Universitaire de Angers
405 schema:name Division of Hematology, University Hospital of Angers, France
406 rdf:type schema:Organization
407 https://www.grid.ac/institutes/grid.411162.1 schema:alternateName Centre Hospitalier Universitaire de Poitiers
408 schema:name Oncology-Hematology and Cell Therapy, CHU la Milétrie, Poitiers, France
409 rdf:type schema:Organization
410 https://www.grid.ac/institutes/grid.411167.4 schema:alternateName Centre Hospitalier Universitaire de Tours
411 schema:name Division of Hematology, University Hospital of Tours, France
412 rdf:type schema:Organization
413 https://www.grid.ac/institutes/grid.411766.3 schema:alternateName Centre Hospitalier Régional Universitaire de Brest
414 schema:name Division of Hematology, University Hospital of Brest, France
415 rdf:type schema:Organization
416 https://www.grid.ac/institutes/grid.412220.7 schema:alternateName Hôpitaux Universitaires de Strasbourg
417 schema:name Division of Hematology, University Hospital of Strasbourg, France
418 rdf:type schema:Organization
419 https://www.grid.ac/institutes/grid.413852.9 schema:alternateName Hospices Civils de Lyon
420 schema:name Division of Hematology, University Hospital of Lyon, France
421 rdf:type schema:Organization
422 https://www.grid.ac/institutes/grid.42399.35 schema:alternateName Centre Hospitalier Universitaire de Bordeaux
423 schema:name Division of Hematology, University Hospital of Bordeaux, France
424 rdf:type schema:Organization
425 https://www.grid.ac/institutes/grid.4817.a schema:alternateName University of Nantes
426 schema:name Division of Hematology, University of Nantes, France
427 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...